Sunitinib with its more prominent vasculature normalization effects led to greater and sustained decline in tumor Ki67 than bevacizumab in this study, highlighting the promise of normalizing tumor vasculature to optimize chemotherapy delivery in breast cancer. Here, MKI67 is linked to neoplasm.